Authors :
Dr. Vandana Shenoy; Mithun Desikan R; Arunsurya B; Hariharan B; Dr. Senthil kumar
Volume/Issue :
Volume 7 - 2022, Issue 11 - November
Google Scholar :
https://bit.ly/3IIfn9N
Scribd :
https://bit.ly/3FDS5Ce
DOI :
https://doi.org/10.5281/zenodo.7453566
Abstract :
Oral anticoagulants (OACs) are frequently
used for the treatment and prevention of deep vein
thrombosis and pulmonary embolism in patients with
atrial fibrillation and/or heart valve prosthesis. In order to
obtain the desired therapeutic effect and minimise the side
effects associated with both excessive anticoagulation and
the management of these drugs, proper monitoring and
dose adjustment is necessary (which causes bleeding) and
with insufficient antithrombotic action (which can produce
thrombosis). This is essential for people who need to have
surgical procedures like teeth extractions. Numerous
guidelines are available in this context for the management
of anticoagulated patients scheduled for tooth extractions.
The majority of studies do not advise reducing or stopping
anticoagulation before tooth extraction, as long as
therapeutic international normalised ratio (INR) levels are
kept constant for the management of haemostasis.
Oral anticoagulants (OACs) are frequently
used for the treatment and prevention of deep vein
thrombosis and pulmonary embolism in patients with
atrial fibrillation and/or heart valve prosthesis. In order to
obtain the desired therapeutic effect and minimise the side
effects associated with both excessive anticoagulation and
the management of these drugs, proper monitoring and
dose adjustment is necessary (which causes bleeding) and
with insufficient antithrombotic action (which can produce
thrombosis). This is essential for people who need to have
surgical procedures like teeth extractions. Numerous
guidelines are available in this context for the management
of anticoagulated patients scheduled for tooth extractions.
The majority of studies do not advise reducing or stopping
anticoagulation before tooth extraction, as long as
therapeutic international normalised ratio (INR) levels are
kept constant for the management of haemostasis.
